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Abstract  
Dermatofibrosarcoma protuberans (DFSP) is rare mesenchymal neoplasia with a high risk of local recurrence but 
a low risk of metastatic spread. Tumor cells express CD34 and show a characteristic translocation 
t(17;22)(q22;q13). We analysed the documented cases at the Department of Dermatology and Allergology 
between 08/2001 and 08/2017. The diagnosis had been confirmed by histology and immunohistology in all cases. 
We identified four adults and a pediatric patient with DFSP. All patients were treated by wide surgical excision and 
controlled by three-dimensional histologic margin control. We observed no recurrence and no metastatic spread. 
We discuss prognostic factors and emerging treatments. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Dermatofibrosarcoma protuberans (DFSP) is 
rare mesenchymal neoplasia of skin and soft tissue. 
Most cases develop on trunk and extremities as 
nodules or plaques, sometimes hyperpigmented. The 
hyperpigmented type is also known as Bednar a 
tumour. There is a wide age range, although 
incidence shows a peak between the second and fifth 
decade of life.  
Diagnosis is made by histology, 
immunohistology and cytogenetic analysis [1]. 
DFSP is characterised by a relatively high risk 
of local recurrence but low risk of metastatic spread. 
In most cases, a chromosomal translocation can be 
found: t(17;22)(q22;q13). Thereby, the genes COL1A1 
and platelet-derived growth factor (PDGF)-beta fuse. 
This leads to an autocrine stimulation loop involving 
PDGF-beta and PDGF-beta receptor [2]. 
We analysed our files for DFSP-patients, 
treatment, and outcome and discussed emerging 
treatments. 
 
 
Material and Methods 
 
We analysed the files of the Department of 
Dermatology and Allergology, Academic Teaching 
Clinical Science 
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Hospital Dresden during a 16-year period, i.e. 08/2001 
to 08/2017. Demographics, tumour characteristics, 
treatment and outcome, were investigated. 
 
 
Results 
 
We were able to identify five patients with a 
histologically confirmed diagnosis of DFSP. Maximal 
tumour diameter was between 2 and 4 cm. All 
tumours were staged T1(≤ 5 cm of tumour diameter 
on trunk and extremities), N0, M0, G1 (low grade). All 
tumours were ordinary DFSP without 
fibrosarcomatous transformation. One tumour was 
hyperpigmented (Bednar type). 
The youngest patient was a 10-year-old girl 
with a rapidly growing, painless nodule of the chest 
(Fig. 1). A diagnostic skin biopsy was taken, that 
revealed large uniform spindle cells reactive with 
CD34 but negative for S100. Several mitoses were 
noted. The proliferative fraction as measured by Ki67-
reactivity was 1%. A tumour was removed by wide 
surgical excision with 2 cm safety margin and 
complete removal of soft tissue down to the muscle 
fascia by slow Mohs technique. 3-dimensional 
histologic margin control was performed. The resulting 
defect was closed by tissue advancement flap after 
wide subcutaneous mobilisation of wound margins. 
Healing was uneventful. The 5-year follow-up was 
relapse-free. 
 
Figure 1: Juvenile dermatofibrosarcoma protuberans on the chest of 
a 10-year-old girl. (a) Clinical presentation of a well-circumscribed 
plaque; (b) Defect after wide excision 
 
The remaining patients were adults aged 24, 
27, 43, and 61 years of age. The sex ratio for the adult 
patients was 1:1. One female patient was referred 
with a recurrence after first surgery elsewhere. The 
localisation was a shoulder, hip, epigastrium and 
under belly (Fig. 2).  
The safety margins were 1 – 4 cm according 
to German guidelines [3][4]. In all patients, tumour-
free margins were documented. In 4 of five tumours, 
only one surgical session was necessary, in a single 
tumour two sessions were needed to obtain tumour-
free margins. 
 
Figure 2: Nodular dermatofibrosarcoma protuberans on the 
underbelly of a 61-year-old male patient. (a) Clinical presentation; 
(b) Safety margins; (c) Defect after wide excision; (d) Defect closure 
by tissue advancement 
 
Tumor cells were positive for CD34 but 
negative for S100, desmin, pan-cytokeratin, epithelial 
membrane antigen, and actin. The proliferative index 
was 1% to 10% measured by Ki67 reactivity. Tumor 
staging excluded metastatic spread.  
Defect closure could be realised by tissue 
advancement flaps; no grafts were needed. During 
follow up of up to 7 years neither recurrence nor 
metastasis was noted.  
 
 
Discussion 
 
DFSP is rare mesenchymal neoplasia 
composed of CD34-positive spindle cells. The 
incidence of this tumour has been estimated between 
0.4 and 4.1 patients per million person-years [5][6][7]. 
The 10-year survival is 99.1%. Negative factors for the 
unfortunate outcome are higher age, male sex, black 
race, and anatomic location of the limbs and head 
[7][8].  
Recently, fibrosarcomatous differentiation has 
been identified as a risk factor for local recurrence [9]. 
The transformation also increases the rate of 
metastasis (risk ratio 5.5) and death from disease (risk 
ratio 6.2) [10]. The fibrosarcomatous transformation is 
accompanied by an activation of the Akt-mTOR 
signalling pathway [11]. Treatment of choice is wide 
tumour excision. Safety margins of 2 cm had a 
recurrence rate of 1% [12][13][14]. Patients treated 
with classic or slow Mohs technique have significantly 
lower recurrence rates [15][16].  
DFSP is unresponsive to classical 
chemotherapy. PDGF-beta, KIT and Abelson murine 
leukaemia viral oncogene homolog 1 (ABL) inhibitor 
imatinib mesylate achieved an objective response rate 
of about 50% in DFSP [17]. In metastatic disease, 
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imatinib mesylate resulted in median survival 
progression of ≥ 19 months. The fibrosarcomatous 
transformation had a less favourable outcome 
[18][20]. Emerging new drug therapies for advanced 
or metastatic DFSP are multikinase inhibitors 
pazopanib [21] and regorafenib [22]. 
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